Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
Vertex Pharmaceuticals (Nasdaq: VRTX) has announced a partnership with basketball world champion Jayson Tatum to promote JOURNAVX®, their FDA-approved non-opioid medication for moderate-to-severe acute pain treatment. The partnership highlights Tatum's personal experience using JOURNAVX while recovering from an Achilles tendon injury during the 2025 playoffs.
Tatum chose JOURNAVX as an alternative after experiencing side effects from traditional opioid pain medication following his surgery. Dr. Martin J. O'Malley, Clinical Professor at the Hospital for Special Surgery, confirmed the medication's effectiveness in managing Tatum's post-operative pain. JOURNAVX represents the first new class of pain medicine approved in over 20 years.
Vertex Pharmaceuticals (NASDAQ:VRTX) has secured a reimbursement agreement with the Italian Medicines Agency (AIFA) for CASGEVY®, its CRISPR/Cas9 gene-edited therapy. The agreement covers eligible patients with transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
Italy represents a significant market with approximately 5,000 people aged 12 and older living with TDT and 2,300 with SCD, marking the largest TDT population in Europe. This agreement adds Italy to the growing list of countries providing reimbursement for CASGEVY, including Austria, Bahrain, Denmark, England, Saudi Arabia, and the UAE.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced that Senior Vice President Paul Negulescu has been awarded the prestigious 2025 Lasker~DeBakey Clinical Medical Research Award. The recognition comes for his pivotal role in developing TRIKAFTA®, a groundbreaking triple-drug combination therapy for cystic fibrosis (CF).
Dr. Negulescu shares the award with former Vertex scientist Jesús González and University of Iowa Professor Michael Welsh. The award acknowledges Vertex's achievements in developing five transformational medicines that address the underlying cause of CF, including TRIKAFTA® and ALYFTREK®, which have revolutionized CF treatment for thousands of patients worldwide.
Vertex Pharmaceuticals (NASDAQ:VRTX) has entered into a strategic collaboration with Enlaza Therapeutics to leverage Enlaza's proprietary War-Lock™ technology platform for developing covalent biologics. The partnership focuses on creating small format drug conjugates and T-cell engagers for autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia treatments.
The collaboration includes a $45 million initial investment combining upfront payment and equity investment, with potential for over $2 billion in milestone payments plus tiered royalties. Enlaza will lead research through candidate nomination, while Vertex will manage subsequent development, manufacturing, and commercialization. The four-year collaboration's research and development costs will be funded by Vertex.
This partnership aims to enhance Vertex's CASGEVY® therapy, the first approved CRISPR/Cas9 gene-edited treatment, by developing gentler conditioning methods.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced its management team's participation in three major healthcare investor conferences in September 2025. The company's executives will participate in fireside chats at the Wells Fargo Healthcare Conference (September 3), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference in London (September 23).
Key participants include CEO Reshma Kewalramani, Chief Commercial Officer Duncan McKechnie, and Senior VP of Investor Relations Susie Lisa. All sessions will be available via webcast on Vertex's website with replays archived in the Investors section.
Vertex Pharmaceuticals (NASDAQ:VRTX) announced disappointing topline results from its Phase 2 study of VX-993, a selective NaV1.8 pain signal inhibitor for acute pain treatment. The study, involving 367 patients undergoing bunionectomy surgery, failed to meet its primary endpoint of demonstrating statistically significant improvement in pain reduction (SPID48) compared to placebo.
The trial tested three dosage levels of VX-993 against placebo and a hydrocodone/acetaminophen reference arm. While the drug was generally safe and well-tolerated with no serious adverse events, Vertex will not advance VX-993 into pivotal development as monotherapy in acute pain due to its failure to show superior efficacy compared to existing NaV1.8 inhibitors.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported strong Q2 2025 financial results with total revenue of $2.96 billion, up 12% year-over-year. The company reiterated its full-year 2025 revenue guidance of $11.85-$12.0 billion.
Key highlights include successful launches of CASGEVY, ALYFTREK, and JOURNAVX. The company reported GAAP and non-GAAP net income of $1.0 billion and $1.2 billion respectively. Cash position strengthened to $12.0 billion as of June 30, 2025.
Additionally, Vertex announced that CSO David Altshuler will retire in August 2026, with Mark Bunnage taking over as CSO in February 2026. The company continues to advance multiple clinical programs and expand its commercial presence globally.
KBRA has assigned preliminary ratings to five classes of VRTX 2025-HQ, a CMBS single-borrower securitization backed by a $600 million portion of a $1.0 billion fixed-rate mortgage loan. The loan is secured by Vertex Pharmaceuticals' (NASDAQ: VRTX) headquarters, consisting of two 15-story, Class-A, LEED Gold office towers in Boston's Seaport district.
The property spans 1.1 million square feet, with Vertex occupying 96.8% of the rentable space. The pharmaceutical company recently extended its lease through 2044. The loan features a five-year term with monthly interest-only payments at a 6.25% interest rate. KBRA's analysis yielded a net cash flow of $87.6 million and a property value of $1.06 billion, resulting in a KBRA Loan to Value ratio of 94.2%.
Vertex Pharmaceuticals (NASDAQ:VRTX) has secured a broad reimbursement agreement with NHS England for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), its fifth cystic fibrosis (CF) medicine. The treatment, approved for CF patients aged 6 years and older with specific genetic mutations, received a positive final draft recommendation from NICE.
ALYFTREK® demonstrated superior potential outcomes compared to KAFTRIO® in pivotal studies. The medicine is also becoming available in Ireland, Denmark, and Germany, with Vertex working to expand access across the European Union.
Vertex Pharmaceuticals (Nasdaq: VRTX) has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. for its groundbreaking product JOURNAVX™ (suzetrigine). The recognized treatment is a first-in-class, non-opioid oral medication that works as a selective NaV1.8 pain signal inhibitor for treating moderate-to-severe acute pain in adults.
The recognition comes from Premier's annual Innovation Celebration program, which received approximately 120 nominations this year. Vertex will be formally honored at Premier's Breakthroughs Conference and Exhibition on July 15, 2025.